OrbiMed’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

OrbiMed’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,023	Closed	-$152K	–	136
2024 Q2	$152K	Hold	18,023	–	–	﹤0.01%	114
2024 Q1	$278K	Hold	18,023	–	–	0.01%	113
2023 Q4	$249K	Hold	18,023	–	–	0.01%	110
2023 Q3	$206K	Hold	18,023	–	–	﹤0.01%	127
2023 Q2	$449K	Hold	18,023	–	–	0.01%	123
2023 Q1	$654K	Hold	18,023	–	–	0.01%	119
2022 Q4	$1.09M	Hold	18,023	–	–	0.02%	109
2022 Q3	$1.35M	Hold	18,023	–	–	0.03%	124
2022 Q2	$2.06M	Sell	18,023 -58,670	-76%	-$6.88M	0.04%	130
2022 Q1	$14.5M	Buy	76,693 +6,548	+9%	+$1.52M	0.24%	81
2021 Q4	$24.3M	Buy	70,145 +3,528	+5%	+$1.37M	0.31%	77
2021 Q3	$22.4M	Hold	66,617	–	–	0.25%	91
2021 Q2	$54.9M	Buy	+66,617	New	+$51.6M	0.56%	53

Other funds holding OMIC

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

QVIDTVM Management The Woodlands, Texas $76.6M AUM 33.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's OMIC Position: Q3 2024 in Review

OrbiMed sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2024, closing a stake of 18,023 shares — an estimated $152K sold.

OrbiMed first reported a position in OMIC in Q2 2021 and held it in 13 quarters. The position peaked at $54.9M in Q2 2021. 22 funds tracked by Wall St. Rank hold OMIC as of Q3 2024.

OrbiMed reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 18,023 Singular Genomics Systems, Inc. Common Stock shares in Q3 2024, an estimated $152K.
OrbiMed first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
OrbiMed's Singular Genomics Systems, Inc. Common Stock position peaked at $54.9M in Q2 2021.
22 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.